180 Life Sciences Corp (ATNF)
1.62
+0.01
(+0.62%)
USD |
NASDAQ |
May 31, 16:00
1.63
+0.01
(+0.62%)
After-Hours: 20:00
180 Life Sciences Research and Development Expense (Quarterly): 0.5357M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 0.5357M |
December 31, 2023 | -0.0364M |
September 30, 2023 | 1.105M |
June 30, 2023 | 0.9209M |
March 31, 2023 | 0.795M |
December 31, 2022 | 0.5857M |
September 30, 2022 | 0.6365M |
June 30, 2022 | 0.5037M |
March 31, 2022 | 0.7067M |
Date | Value |
---|---|
December 31, 2021 | 1.972M |
September 30, 2021 | 0.6154M |
June 30, 2021 | 0.9945M |
March 31, 2021 | 0.367M |
December 31, 2020 | 0.8589M |
September 30, 2020 | 0.4996M |
June 30, 2020 | 0.4311M |
March 31, 2020 | 0.5035M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-0.0364M
Minimum
Dec 2023
1.972M
Maximum
Dec 2021
0.7055M
Average
0.6154M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
Seelos Therapeutics Inc | 3.525M |
GT Biopharma Inc | 0.777M |
Altimmune Inc | 21.49M |
Oragenics Inc | 0.6634M |
MAIA Biotechnology Inc | 2.321M |